News stories about Teva Pharmaceutical Industries (NYSE:TEVA) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries earned a news impact score of 0.17 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.1604812214831 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Applied Materials among leaders despite poor month perfor… (finance.yahoo.com)
- Zacks: Brokerages Anticipate Teva Pharmaceutical Industries Limited (TEVA) to Post $0.80 Earnings Per Share (americanbankingnews.com)
- Teva Pharmaceutical Industries (TEVA) Stock Rating Upgraded by ValuEngine (americanbankingnews.com)
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) – Today’s Hot Mover – Alpha Beta Stock (alphabetastock.com)
- Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Trending Hot Stock’s Analysis – Nasdaq Journal (press release) (nasdaqjournal.com)
Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded down $0.74 during trading on Wednesday, hitting $14.32. 22,050,378 shares of the company’s stock were exchanged, compared to its average volume of 15,674,337. The firm has a market capitalization of $15,290.80, a P/E ratio of 3.48 and a beta of 0.55. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $38.31. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96.
A number of research analysts recently commented on TEVA shares. Deutsche Bank reaffirmed a “buy” rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, August 9th. BTIG Research raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Monday, September 11th. Gabelli reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 13th. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Finally, Evercore ISI set a $38.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Wednesday, October 25th. Seven research analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $21.65.
WARNING: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://stocknewstimes.com/2017/12/06/teva-pharmaceutical-industries-teva-receiving-somewhat-favorable-press-coverage-report-finds.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.